Company: SINT
Filing Date: 2025-10-03
Form Type: 424B5
Source: 0001493152-25-016902
Chunk: 9

Company: Sintx Technologies, Inc.
Filing Date: 2025-10-03
Form: 424B5
Chunk 9
---
 2022 Warrants are exercisable at an exercise price of $4.20 per share. The Series B convertible preferred stock and October 2022 Warrants contain full-ratchet anti-dilution provisions which, subject to limited exceptions, would reduce the conversion price of the Series B preferred stock (and increase the number of shares issuable under the Series B preferred stock) and reduce the exercise price of the October 2022 Warrants in the event that we in the future issue Common Stock, or securities convertible into or exercisable to purchase Common Stock, at a price per share lower than the conversion price or exercise price then in effect. On February 10, 2023, the Company closed on a public offering of 10,750 units, with each unit consisting of one share of common stock, or one pre-funded warrant to purchase one share of its common stock, one Class C warrant to purchase one share of common stock (the “Class C Warrants”), and one half of one Class D warrant with each whole Class D Warrant entitling the holder to purchase one share of common stock (the “Class D Warrants”). The Class C Warrants and Class D Warrants include alternative cashless exercise provisions allowing for such warrants to be cashless exercised in an amount equal to 80% of the shares for which such warrants are exercisable on a cash basis. The alternative cashless exercise provisions contained in the Class C Warrants and Class D Warrants could potentially result in a significant reduction in the conversion or exercise price of the Series B convertible preferred stock and October 2022 Warrants.

The issuance of Common Stock upon exercise of these warrants, or the sale of Common Stock in any offering, including this offering, could trigger the full-ratchet anti-dilution provisions of the Series B convertible preferred stock and October 2022 Warrants if such shares are issued or sold at prices below the then conversion price of the Series B preferred stock or exercise price of the October 2022 Warrants. A reduction in the conversion price of the Series B preferred stock would increase the number of shares of our Common Stock issuable upon conversion of the Series B preferred stock. The shares of Common Stock sold in this offering, if any, will be sold from time to time at various prices, and this “full-ratchet” anti-dilution provision will be triggered if the Common Stock is sold in this offering at a price below the then conversion price of the Series B preferred stock or exercise price of the October 2022